LGND - Ligand Corp Total Debt to Capital

Ligand Pharmaceuticals (LGND) protects its business through exclusive platform rights and payments from major industry players under strict FDA supervision. The company operates as a financial hub, collecting royalties without maintaining its own production, which allows it to minimize headcount through automation. The current separate_debt_total_eq ratio stands at 1.15. The trend of this metric is reflected in the company's price chart.

This ratio reflects the proportion of total liabilities to equity, determining the extent of Ligand Pharmaceuticals (LGND) reliance on borrowed funds. By analyzing the business's leverage ratio, investors assess the company's financial stability, which minimizes capital expenditures through a licensing model and royalty streams, ensuring high scalability without excessive credit pressure.